Search
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigationalIt consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]
Synonyms: Lu-177-PSMA-617, lutetium Lu 177-PSMA-617Categories: Compounds used in a research, industrial, or household settingOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalDeveloped by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalIt was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism
Categories: Bispecific gp100 Peptide-HLA-directed CD3 T Cell EngagerGlecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalIn clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L41080 … In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsIpratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigationalIpratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent. … ] was approved in 1996.
Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, BERODUAL N METERED DOSE INHALERProducts: Penta-ipratropium Bromide, Aa-ipraventPrilocaine
go.drugbank.com/drugs/DB00750ApprovedInvestigationalA local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)
Synonyms: alpha-n-Propylamino-2-methylpropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamideMixtures: LIDOCAINA E PRILOCAINA TEVA, LIDOCAINA E PRILOCAINA TEVAGrazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … in combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593].
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalUse of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours). … If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, Soliqua SoloStar 100units/mL+50mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in Diabetes, Complex MixturesMarnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients.
Synonyms: Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 gene, Hematopoietic stem cells modified with a lentiviral vector containing the CD18 (integrin beta 2) gene